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Cytokines, hormonelike proteins, produced by stimulated cells and tissues, were found to protect
mice against lethal hematopoietic failure caused by ionizing radiation. Radioprotection was
achieved by pretreatment with interleukin-1 (IL-1), tumor necrosis factor (TNF), IL-12, or stem cell
factor (SCF) at 18 to 24 hr before irradiation. Pretreatment with antibodies to these cytokines
rendered the mice more susceptible to radiation lethality, indicating that these cytokines play a
role in innate resistance to radiation. In contrast, treatment with tumor growth factor beta (TGF-P),
a cytokine that inhibits cycling of primitive hematopoietic progenitors, sensitized mice to radiation
lethality. The schedule of IL-1 administration was critical to its radioprotective effect. Evidence
was obtained that this may be based on the induction of additional cytokines by IL-1. The
radioprotective effects of cytokines can be based on induction of cycling of primitive progenitor
cells (IL-1, SCF), prevention of apoptosis (SCF), and induction of scavenging proteins and
enzymes (IL-1, TNF) that reduce oxidative damage. In contrast, radiosensitizing effects may be
due to inhibition of progenitor cycling (TGF-p) or enhanced progenitor cell apoptosis (TGF-0). Thus,
the insights gained from such studies at the whole-animal level promise a better understanding of
the membrane and intracellular events associated with radiation damage and repair of such
damage. Environ Health Perspect105(Suppl 6):1463-1465 (1997)
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Introduction
Studies in the 1950s indicated that death
attributable to hematopoietic damage
caused by ionizing radiation can be pre-
vented by pretreatment with immuno-
modulatory agents (1). Such agents were
recognized to stimulate the reticulo-
endothelial system, but their mechanism
of action has not been well defined. The
subsequent finding that proinflammatory
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cytokines can confer radioprotection (2)
facilitated a more direct approach to study
such mechanisms ofprotection.
Cytokines produced by stimulated cells
and tissues are hormonelike proteins that
serve in either autocrine, paracrine, and at
times, endocrine fashion, as intercellular
messengers. A number ofcytokines: inter-
leukin-1 (IL-1), tumor necrosis factor
(TNF), and IL-6 stimulate a broad range
of cell and tissue activities (3). These
diverse effects depend on the type of sig-
naling receptor and on components ofthe
signal transducing pathway engaged in a
given cell, which leads at times to the sub-
sequent activation ofdifferent transcription
factors. For example, it was recently found
that upregulation or the lack ofupregula-
tion ofthe nuclear factor KB (NFKB) lead
to a seemingly paradoxic observation-that
TNF may lead to apoptosis of some cells
yet induce proliferation or differentiation
ofothers (4).
As the characteristics and modes of
action ofcytokines are becoming rapidly
understood, the basis for their protective
and/or restorative action is being delin-
eated and should aid in developing a better
understanding ofthe role ofinflammatory
pathways in producing radiation damage
and ofprotection against such damage. Such
understanding should lead to the develop-
ment ofa more optimal treatment aimed at
preventing damage to normal tissues.
Preclinical and clinical studies demon-
strated that a broad range ofcytokines can
serve to accelerate bone marrow restor-
ation following myeloablative cytotoxic
drugs or radiation (5). Although many of
these cytokines such as IL-3, granulocyte
colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating
factor (GM-CSF), macrophage colony-
stimulating factor (M-CSF), IL-6, IL- I1,
erythropoietin (EPO), thrombopoietin
(TPO), or stem cell factor (SCF) affect
primarily proliferation and differentiation
ofhematopoietic cells at various stages of
their lineage progression, other cytokines
such as IL-1, IL-4, or interferon gamma
(IFN-'y) are also myelorestorative. In con-
trast, only a few ofthe cytokines, for exam-
ple IL-1, TNF, SCF, and IL-12, protect
animals when given 20 hr before ad-
ministration of lethal doses of radiation.
Several additional cytokines, including
TGF-0 and IFN-ac/4, sensitize to radiation
lethality (6).
This paper briefly reviews several ofour
findings: a) evidence for an important role
that IL-1, TNF, IL-6, and SCF play in
innate defenses against ionizing radiation;
b) evidence that cytokines act in a network,
i.e., following cytokine administration to
a host, a cascade of additional cytokines
and other mediators are induced at differ-
ent times leading to different outcomes
depending on the treatment regimen; and
c) evidence that the same cytokine may
have opposing effects on different tissues.
Cytokines in Radioprotection
and Innate Resistance
to Radiation
Administration of cytokines IL-1, TNF,
SCF, or IL-12 given within 18 to 24 hr
before irradiation protects mice from
death. Conversely, anti-IL-1, anti-TNF
antibodies, and anti-SCF antibodies in
mice not treated with cytokines resulted in
LD50/30 doses ofradiation becoming lethal
to 100% of mice, indicating that the
endogenous production of each of these
cytokines contributes to innate radiation
tolerance (7,8). Such results provided
direct evidence that these cytokines act as
endogenous radioprotectors.
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Several cytokines were found to
synergize in radioprotection. For example,
pombined administration of IL-I and
TNF or IL-1 and SCF resulted in radio-
protection at doses of radiation at which
neither of these cytokines was protective
when given separately (8,9). Furthermore,
the antibody to the IL-1 receptor blocked
TNF-induced radioprotection, whereas
t4e antibody to the TNF blocked IL-1-
induced radioprotection. The antibody to
SCF blocked IL-1 and TNF induced
radioprotection, whereas the antibody to
the IL-1 receptor blocked SCF radio-
protection. IL-1 also synergized with
IL-6, GM-CSF, and G-CSF. However,
since IL-1 induces the production of all
three of these cytokines, this synergy
could be observed only at suboptimal
radioprotective doses of IL-1. Thus, the
contribution of numerous cytokines to
radioprotection seems to be a prerequisite
for optimal radioprotection. Each ofthese
cytokines was shown to be upregulated
after animal exposure to ionizing radiation
(10), providing support for the hypothesis
that the therapeutic effects ofthe supple-
mentary pharmacological doses of these
cytokines may be exerted by amplifying
the levels of endogenously induced
cytokines with the capacity to promote
reparative processes.
Cytokine Cascades Determine
Protection and Damage
from Injury
IL-I is a potent in vivo stimulator of
hemopoiesis partly because of its capacity
to induce production of hematopoietic
growth factors and to upregulate their
receptors on bone marrow progenitors
(11). Several hours after administration of
a single dose ofIL-I the number ofhemo-
poietic progenitors in the bone marrow
increases and reaches a maximum after 48
hr. These earlyfindings suggest that expan-
sion of progenitor cells may be the basis
for the myeloprotective action of IL-1.
However, since mice receiving irradiation
48 hr after IL-1 treatment are not pro-
tected from death (12), the mere increase
in the numbers ofprogenitor cells is not
sufficient for IL-1 radioprotection.
The kinetics of the radioprotective
effect ofIL-1 suggest that this effect may
be attributed to the cycling ofprogenitor
cells and to the increased radioresistance of
the cells in the late S-phase ofthe cell cycle
(13). Indeed, the administration of IL-1
18 to 24 hr before irradiation that leads to
optimal radioprotection coincides with
increased sensitivity ofprogenitor cells to
hydroxyurea (HU), selectively toxic for
cells in the S-phase. Similarly, pretreat-
ment with IL-I ofmice receiving sublethal
doses of5-fluorouracil (5-FU), a drug that
spares early progenitor cells because of
their quiescence but is highly toxic to
cycling cells, resulted in death ofmice and
in survival of only 2% of the primitive
hematopoietic progenitor cells (12). Death
occurred only when IL-1 was given 18 to
24 hr, but not 4 or 48 hr, prior to admin-
istration of 5-FU. Apparently IL-1 in-
duced the remaining 98% of these
normally 5-FU-resistant, slow-proliferat-
ing, or quiescent cells to cycle, perhaps
synchronously reaching S-phase at 18 to
24 hr. On the other hand, after 48 hr IL-1
no longer sensitized mice to subsequent
sublethal doses of5-FU and did not affect
significantly the numbers of surviving
progenitor cells, suggesting that the IL-1-
induced cycling effect was transient.
In contrast to radioprotection by
pretreatment with a single dose of IL-1 at
18 to 24 hr, two injections of IL-1 48 hr
apart, at 72 and 24 hr before irradiation,
abrogated radioprotection and the sensitiv-
ity ofprogenitor cells to 5-FU (12). These
findings suggest that 48-hr pretreatment
with IL-1 results in abrogation of the
ability ofthe early progenitors to cycle in
response to subsequent IL-1 challenge.
This effect may be based on observed
increased expression ofTGF-P mRNA and
protein (12).
TGF-4 has been reported to be a
potent inhibitor ofthe cell cycle for many
cell types, acting through the reduction of
the expression of multiple growth factor
receptors, including c-kit, a receptor for
SCF expressed on early hematopoietic
progenitors, SCF production, and through
activation ofcell-cycle inhibitors. TGF-j
inhibited the in vitro growth ofprimitive
progenitor cells high proliferative potential
colony-forming cells (HPP-CFC) (14).
In addition to TGF-,, other factors
induced by IL-1 and inhibitory to cycling
and proliferation ofhematopoietic progen-
itors such as prostaglandin and TNF, both
of which are induced by IL-1, were
reported to inhibit the growth of progeni-
tor cells. Thus, a cascade ofcytokines and
other mediators induced by IL-1 includes
positive as well as negative regulators of
cyclingofprimitive progenitors.
Together these findings suggest
that a given cytokine action depends
heavily on temporal cascades ofcytokines
leading to various outcomes at different
treatment schedules.
Contrasting Effects of IL-12
on Hematopoietic and
Gastrointestinal Tissues
IL-12 has potent antitumor and anti-
metastatic activity in a number ofmurine
tumor models (15). This property, along
with the observation that it is a stimulator
ofthe early hematopoietic progenitor cells,
suggest that in addition to playing an
important role in cancer therapy IL-12
may act as a myeloprotector. Indeed,
administration of IL-12 within 24 hr
before otherwise lethal irradiation pro-
tected a significant fraction of mice from
lethal hematopoietic syndrome (16). The
radioprotection was associated with a sig-
nificant increase in the numbers ofhemo-
poietic progenitor cells found in marrow 3
days after administration of 1200 cGy.
IL-12, however, radiosensitized, not radio-
protected, the gastrointestinal tract as evi-
denced in mice that died within 4 to 6
days after receiving IL-12 and 1200 cGy.
The gastrointestinal syndrome was docu-
mented by gross necroscopy and histologic
evaluation. Induction of a similar syn-
drome in mice not treated with IL-12
required doses greater than 1600 cGy.
Thus, at doses ofradiation at which IL-12
still protects bone marrow cells, it sensitizes
the intestinal tract to radiation damage.
Although protection ofhematopoietic cells
was abrogated with anti-IL-lR and anti-
SCF antibody, sensitization of the intesti-
nal tract was prevented with anti-IFNyand
anti-TNF antibody (15). Thus, different
cytokines are involved in IL-12 protection
ofthe bone marrow than in its sensitizing
effect on the gut.
Sensitization ofthe gut epithelial cells
by IL-12-induced IFNy may be associated
with this cytokine's ability to upregulate Fas
antigen. This has been demonstrated for
lymphocytes and for CD34+ hematopoietic
progenitor cells. Although freshly isolated
CD34+ cells do not express Fas antigen,
stimulation of these cells with IFNy or
TNF-a markedly increased this antigen
expression. Ligation ofFas in the presence
of IFNy or TNF-a induces apoptosis of
hematopoietic progenitor cells. It is there-
fore possible that IL-12-induced IFNy and
TNF upregulate gut epithelial cells apopto-
sis through similar mechanisms, leading to
exacerbated gut destruction in irradiated
mice. In contrast to the detrimental effect
on the gut epithelial cells, IFNy has been
used as a sensitizer in solid tumors.
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Conclusions
Complete understanding ofhow cytokines
are radioprotective at the cellular level will
only be achieved when we understand
how the irradiated cells die. Apoptotic
death is presumed to occur in hemato-
poietic stem cells. There is little direct
information about the radiation-induced
apoptotic process in these cells because
they are rare cells in the host tissues, and
culturing them outside the host environ-
ment requires conditions that probably are
not physiological.
Several possible mechanisms of radio-
protection by cytokines have emerged:
a) reduction ofoxidative damage through
induction ofmitochondrial enzymes such
as MnSOD, and other scavenging proteins,
as demonstrated for IL-1, TNF, and IL-6;
b) reduction ofapoptotic response through
induction of bcl-2 by SCF; and c) induc-
tion ofnormally quiescent early progenitor
cells to enter the cell cycle and possibly
reach the relatively radioresistant late
S-phase, as suggested by the kinetics ofIL-I
and SCF radioprotection and the suscepti-
bility these cells develop to cycle-dependent
drugs HU and 5-FU.
In contrast, the sensitizing mechanisms
may include: a) increased oxidative dam-
age that may occur in the absence ofscav-
enger induction, as observed for TNF for
many tumor cell line; b) enhanced apop-
tosis by upregulation of Fas antigen, as
reported for TNF and IFN'y or activation
ofhydrolysis ofsphingomyelin to ceramide
and subsequent downregulation of bcl-2
mRNA expression; and c) arrest ofcells in
G1 phase ofthe cycle at the time ofexpo-
sure to radiation, which may promote
apoptosis. Although not completely
understood, the growth-arresting effect of
TGF-f may be exerted on several molecu-
lar targets (14). Among the suggested tar-
gets are downregulation of c-myc RNA
and protein levels, downregulation oftran-
scriptional induction of cyclin A and
cyclin E, and upregulation of inhibitors
for cdk-cyclin complexes, p15, p16, p21
and p27. Evidence accumulating from dif-
ferent cell types suggests that there may be
substantial differences between different
cells in the mechanisms by which TGF-,
inhibits their proliferation.
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